Table 1. Comparison of Treatment Guidelines for Stereotactic Body Radiotherapy-Eligible Hepatocellular Carcinoma.

		Guidelines
		BCLC	NCCN	APPLE	KLSCG-NCC
Single, ≤2 cm, without VI	Subgroup	Very early	Resectable or transplantable	Very early	mUICC Stage I
	Primary or preferred option	Resection (or LT/RFA/ PEI, if portal pressure/ bilirubin increased)	Resection or LT	Resection (or LT/RFA/PEI, if portal pressure/bilirubin increased)	Resection or RFA
	Alternative option	(−)	Locoregional treatment (Ablation, arterial directed therapies, EBRT)	EBRT	TACE, PEI, or EBRT
Single, >2 cm, without VI	Subgroup	Early	Resectable or transplantable	Early	mUICC Stage II
	Primary or preferred option	LT or RFA/PEI	Resection or LT	LT or RFA/PEI	Resection or RFA
	Alternative option	(−)	Locoregional treatment (Ablation, arterial directed therapies, EBRT)	SABR, hypofractionated RT	TACE, LT, or EBRT

BCLC, Barcelona clinic liver cancer; NCCN, National Comprehensive Cancer Network; APPLE, Asia Pacific Primary Liver Cancer Expert Meeting; KLCSG-NCC, Korean Liver Cancer Study Group and the National Cancer Center; VI, vascular invasion; LT, liver transplantation; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; EBRT, external-beam radiotherapy; mUICC, modified Union for International Cancer Control; TACE, transarterial chemoembolization; RT, radiotherapy; SABR, stereotactic ablative radiotherapy.